facial acne vulgaris Mild Acne Vulgaris, Skin Microbiome, Intradermal Injection, Hyaluronic Acid , Glycerol, Skin Barrier, Skin Hydration
Conditions
Interventions
Participants will receive intradermal injections of Cohesive Polydense Matrix Hyaluronic Acid (CPM-HA) 20 mg/mL combined with Glycerol 17.5 mg/mL (Belotero Revive) into both cheeks. The treatment will
Experimental Drug
CPM-HA20G
Sponsors
None listed
Eligibility
Sex/Gender
Female
Age
25 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1.Diagnosed with mild acne vulgaris GEA scale 2. 2. Fitzpatrick skin phototypes III to VI
Exclusion criteria
Exclusion criteria: (1) Diagnosed with moderate to severe acne vulgaris (GEA scale grade 3 or higher). (2) Known history of hypersensitivity or allergy to hyaluronic acid, glycerol, or any other components of the product. (3) Known history of allergy to either topical or injectable local anesthetics. (4) Active dermatological conditions in the treatment area, such as psoriasis, dermatitis, or eczema. (5) Ongoing skin infections (viral, fungal, or bacterial) in the treatment area that have not completely resolved. (6) History of using topical acne treatments (e.g., benzoyl peroxide, retinoids, azelaic acid) within the past 1 month. (7) History of using oral antibiotics, or oral isotretinoin within the past 6 month. (8) History of receiving facial dermal fillers or collagen biostimulators within the past 1 year. (9) History of receiving facial botulinum toxin injections within the past 6 months. (10) History of undergoing facial surgery within the past 6 months. (11) History of undergoing facial laser treatments within the past 6 months. (12) Currently pregnant or breastfeeding. (13) Current use of hormonal therapies, such as oral contraceptives, anti-androgens, or hormone replacement therapy (HRT). (14) History of autoimmune or endocrine disorders, such as Systemic Lupus Erythematosus (SLE), Polycystic Ovary Syndrome (PCOS), hyperandrogenism, or irregular menstruation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin Microbiome Analysis 24 weeks Next-Generation Sequencing (16S rRNA gene sequencing) | — |
Secondary
| Measure | Time frame |
|---|---|
| Acne severity 24 weeks GEA scale ( a validated physician-assessed grading system used to evaluate the overall severity of acne vulgaris based on the type, extent, and distribution of acne lesions. (Range from grade 0 to 5) ,Acne severity 24 weeks Acne lesion counts,Sebum production 24 weeks Sebumeter,Transepidermal water loss 24 weeks Tewameter,Stratum corneum hydration 24 weeks Corneometer,Skin pH 24 weeks Skin pH meter,Porphyrin count 24 weeks Trica 3D,Pore size 24 weeks Trica 3D | — |
Countries
Thailand
Contacts
Public ContactKunlathorn Thawinprawat
Thammasat university
Outcome results
None listed